Healthcare / Medical DevicesNasdaqGS
$13.92
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $25.0M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-49.5%
↓Gross Margin
N/A
•Debt/Equity
0.70
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1.9%
FCF / Net income
0.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.64B · net income $-516.5M · FCF $-31.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | $1.64B | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B | $1.37B | $1.52B | $1.47B | $1.19B | $992.1M | — | — | — | — | — | — | — | — |
| Net Income | $-516.5M | $-516.5M | $-6.9M | $67.7M | $180.6M | $169.1M | $133.9M | $50.2M | $60.8M | $64.7M | $74.6M | $-3.5M | $34.0M | $-21.1M | $41.2M | $28.0M | $65.7M | $51.0M | $27.7M |
| EBITDA | — | — | — | — | — | — | — | $203.2M | $221.7M | $133.7M | $188.0M | $138.4M | $114.3M | $66.4M | $126.4M | $105.1M | $137.9M | $137.5M | $78.1M |
| EPS | -6.74 | -6.74 | -0.09 | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 | 0.72 | 0.82 | 0.94 | -0.05 | 0.52 | -0.74 | 1.44 | 0.95 | 2.17 | 1.74 | 0.96 |
| Gross Margin | — | — | — | — | — | — | 62.0% | 62.8% | 61.2% | 63.3% | 64.8% | — | — | — | — | — | — | — | — |
| Operating Margin | -30.2% | -30.2% | 1.8% | 7.2% | 15.3% | 12.8% | 11.0% | 6.2% | 7.5% | 3.8% | 11.6% | — | — | — | — | — | — | — | — |
| Net Margin | -31.6% | -31.6% | -0.4% | 4.4% | 11.6% | 11.0% | 9.8% | 3.3% | 4.1% | 5.4% | 7.5% | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||
| Debt/Equity | 0.70 | 0.70 | 0.49 | 0.49 | 0.43 | 0.50 | 0.58 | 0.62 | 0.65 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $-31.1M | $-31.1M | $25.0M | $73.1M | $222.1M | $264.4M | $164.9M | $161.9M | $121.9M | $71.0M | $69.1M | $71.4M | $45.2M | $11.0M | $-9.9M | $65.9M | $68.4M | $118.0M | $59.2M |
| Returns | |||||||||||||||||||
| ROE | -49.5% | -49.5% | -0.4% | 4.3% | 10.0% | 10.0% | 8.8% | 3.5% | 4.4% | 6.7% | 8.9% | -0.5% | 4.8% | -3.2% | 8.0% | 5.7% | 13.1% | 11.5% | 7.4% |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | 1.5% | 1.5% | 4.5% | -1.0% | 1.0% | 12.4% | -9.6% | 3.1% | 23.9% | 19.8% | — | — | — | — | — | — | — | — | — |
| EPS Growth | -7388.9% | -7388.9% | -110.7% | -61.1% | 9.1% | 26.1% | 170.7% | -19.4% | -12.2% | -12.8% | 1980.0% | -109.6% | 170.3% | -151.4% | 51.6% | -56.2% | 24.7% | 81.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.